Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Küsters Vandevelde, Heidi VN ^a   Willemsen, Annelieke E C A B ^b   Groenen, Patricia JTA ^b   Küsters, Benno ^b   Lammens, Martin ^b,d   Wesseling, Pieter ^a,b,c   Djafarihamedani, Melika ^b   Rijntjes, Jos ^b   Delye, Hans ^b   Willemsen, Michel A ^b   van Herpen, Carla M L ^b   Blokx, Willeke A M ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Leptomeningeal melanocytosis; MEK inhibitor; MEK162; Neurocutaneous melanosis; NRAS; Targeted therapy

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BINIMETINIB; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADOLESCENT; BRAIN; CASE REPORT; GENETICS; HUMAN; MALE; MELANOSIS; MUTATION; NEUROCUTANEOUS SYNDROMES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SPINAL CORD;

ADOLESCENT; BENZIMIDAZOLES; BRAIN; ENZYME INHIBITORS; GTP PHOSPHOHYDROLASES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOSIS; MEMBRANE PROTEINS; MUTATION; NEUROCUTANEOUS SYNDROMES; SPINAL CORD;

EID: 85043617871     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-41     Document Type: Article

References (15)

1. Kadonaga JN, Frieden IJ: Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 1991, 24: 747-755. 10.1016/0190-9622(91)70115-I
2. Rokitansky: Ein ausgezeichneter Fall von Pigment-Mal mit ausgebreiteter Pigmentirung der inneren Hirn- und Rueckenmarkshaute. Allgemeine Wiener Medizinische Zeitung 1861, 15: 113-116.
3. Fox: Neurocutaneous melanosis. In Handbook of Clinical Neurology. Edited by: Vinken PJ, Bruyn GW. New York: Elsevier; 1972:414-428.
4. Brat DJ, Perry A: Melanocytic lesions. In WHO Classification of Tumours of the Central Nervous System. 4th edition. Edited by: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Lyon: IARC; 2007:181-183.
5. Brunsvig KL, Zenobi M, Rilliet B, El Hassani Y, de Haller R, Ansari M, Lobrinus JA, Hanquinet S, Fluss J: Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis. J Child Neurol 2011, 26: 1444-1448. 10.1177/0883073811409749
6. Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Kusters B, Wesseling B, Blokx WA, Marais R: Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 2013, 3: 458-469. 10.1158/2159-8290.CD-12-0464
7. Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Sater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013, 9: 2229-2236.
8. Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010, 3: 317-323.
9. Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A, Pietsch T: GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 2013, 4: 417-425.
10. Kinsler VA, Paine SM, Anderson GW, Wijesekara DS, Sebire NJ, Chong WK, Harkness W, Aylett SE, Jacques TS: Neuropathology of neurocutaneous melanosis: histological foci of melanotic neurones and glia may be undetectable on MRI. Acta Neuropathol 2012, 3: 453-456.
11. Demirci A, Kawamura Y, Sze G, Duncan C: MR of parenchymal neurocutaneous melanosis. Am J Neuroradiol 1995, 16: 603-606.
12. Schreml S, Gruendobler B, Schreml J, Bayer M, Ladoyanni E, Prantl L, Eichelberg G: Neurocutaneous melanosis in association with Dandy-Walker malformation: case report and literature review. Clin Exp Dermatol 2008, 33: 611-614. 10.1111/j.1365-2230.2008.02745.x
13. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14: 249-256. 10.1016/S1470-2045(13)70024-X
14. Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir C, Rehkamper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M: Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013, 31: e173-e174. 10.1200/JCO.2012.46.5773
15. Sloot S, Fedorenko IV, Smalley KS, Gibney GT: Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother 2014, 15: 589-592. 10.1517/14656566.2014.881471